The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

One pundit tracking the company is particularly concerned about the performance of its foundational snacks business.

If management's predictions are accurate, the company is in for a period of sustained growth.

UiPath has struggled this year as its growth rate has been slowing down and it's nowhere near posting a profit. The consensus ...

Nvidia has built a solid position for itself in this fast-growing data center niche that could help generate sizable revenue ...

The pet specialist's largest shareholder is selling a large chunk of stock. It priced this at below Chewy's latest closing ...

Initial public offerings (IPOs) can be great opportunities for investors. After all, getting in on a stock on the ground floo ...

Intel stock closed up 3.3% on the news, after jumping as much as 9.5% when the story first broke. Qualcomm closed down 2.9% ...

New York Community Bancorp isn't realistically poised for sudden and dramatic improvement. The bank expanded too quickly in ...

The Oracle of Omaha has purchased shares of this company for 24 consecutive quarters, dating back to the midpoint of 2018.

UPS shares are falling after archrival FedEx released results that disappointed markets. Shipping companies are suffering ...

Yet its foundry business has shown potential for improvement. Intel will turn that business into a separate subsidiary, ...